特刊“癌症生物标志物研究与个性化医疗”。
Special Issue "Cancer Biomarker Research and Personalized Medicine".
作者信息
Meehan James
机构信息
Translational Oncology Research Group, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, UK.
出版信息
J Pers Med. 2022 Apr 5;12(4):585. doi: 10.3390/jpm12040585.
Abstract
While the term biomarker is thought to have first been used in the 1970s, the concept itself is considered to be much older [...].
摘要
虽然生物标志物这个术语被认为最早在20世纪70年代就已使用，但该概念本身被认为要古老得多[...]。
相似文献
1
Special Issue "Cancer Biomarker Research and Personalized Medicine".特刊“癌症生物标志物研究与个性化医疗”。
J Pers Med. 2022 Apr 5;12(4):585. doi: 10.3390/jpm12040585.
2
Special Issue "Cancer Biomarker Research and Personalized Medicine 2.0".特刊“癌症生物标志物研究与个性化医疗2.0”
J Pers Med. 2024 May 21;14(6):549. doi: 10.3390/jpm14060549.
3
Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.个体化医学与健康经济学和结果研究的作用：问题、应用、新兴趋势和未来研究。
Value Health. 2013 Sep-Oct;16(6 Suppl):S1-3. doi: 10.1016/j.jval.2013.06.004.
4
The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.精准医学中验证的挑战：以切除修复交叉互补组1诊断检测为例。
Oncologist. 2017 Jan;22(1):89-96. doi: 10.1634/theoncologist.2016-0188. Epub 2016 Oct 24.
5
Moving Toward a Precision-Based, Personalized Framework for Prevention Science: Introduction to the Special Issue.迈向精准化、个性化的预防科学框架：特刊导言。
Prev Sci. 2019 Jan;20(1):1-9. doi: 10.1007/s11121-018-0955-9.
6
Personalized medicine in breast cancer: a systematic review.乳腺癌的个体化医学：系统评价。
J Breast Cancer. 2012 Sep;15(3):265-72. doi: 10.4048/jbc.2012.15.3.265. Epub 2012 Sep 28.
7
Enabling personalized medicine in Europe: a look at the European Commission's funding activities in the field of personalized medicine research.在欧洲推动个性化医疗：审视欧盟委员会在个性化医疗研究领域的资助活动。
Per Med. 2012 Mar;9(2):151-155. doi: 10.2217/pme.11.91.
8
Variable Drug-Target Exposure, Tumor Signatures, and Combinatorial Targeted Treatment: Approaches of Personalized Medicine in Breast Cancer.可变的药物-靶点暴露、肿瘤特征与联合靶向治疗：乳腺癌个性化医疗方法
J Pers Med. 2022 Jun 1;12(6):917. doi: 10.3390/jpm12060917.
9
The role of genetic information in personalized medicine.遗传信息在个性化医疗中的作用。
Perspect Biol Med. 2013 Autumn;56(4):485-512. doi: 10.1353/pbm.2013.0040.
10
Translational strategies to implement personalized medicine: rheumatoid arthritis examples.实施个性化医疗的转化策略：类风湿关节炎实例
Per Med. 2009 Jul;6(4):429-437. doi: 10.2217/pme.09.17.
引用本文的文献
1
Maintaining competence in radiation protection research: a position statement by the MELODI scientific advisory committee.保持辐射防护研究能力：MELODI科学咨询委员会的立场声明
Radiat Environ Biophys. 2025 May;64(2):201-209. doi: 10.1007/s00411-025-01122-6. Epub 2025 Mar 28.
本文引用的文献
1
Circulating Tumor Cell Detection during Neoadjuvant Chemotherapy to Predict Early Response in Locally Advanced Oropharyngeal Cancers: A Prospective Pilot Study.新辅助化疗期间循环肿瘤细胞检测预测局部晚期口咽癌早期反应：一项前瞻性初步研究
J Pers Med. 2022 Mar 11;12(3):445. doi: 10.3390/jpm12030445.
2
Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer.基于组织的预后基因组生物标志物在局限性前列腺癌治疗中的应用
J Pers Med. 2022 Jan 7;12(1):65. doi: 10.3390/jpm12010065.
3
Associations between the Levels of Estradiol-, Progesterone-, and Testosterone-Sensitive MiRNAs and Main Clinicopathologic Features of Breast Cancer.雌二醇、孕酮和睾酮敏感型微小RNA水平与乳腺癌主要临床病理特征之间的关联
J Pers Med. 2021 Dec 21;12(1):4. doi: 10.3390/jpm12010004.
4
Exosomes Derived from Radioresistant Breast Cancer Cells Promote Therapeutic Resistance in Naïve Recipient Cells.源自放射抗性乳腺癌细胞的外泌体促进未处理受体细胞的治疗抗性。
J Pers Med. 2021 Dec 6;11(12):1310. doi: 10.3390/jpm11121310.
5
Circulating p16-Positive and p16-Negative Tumor Cells Serve as Independent Prognostic Indicators of Survival in Patients with Head and Neck Squamous Cell Carcinomas.循环中的p16阳性和p16阴性肿瘤细胞是头颈部鳞状细胞癌患者生存的独立预后指标。
J Pers Med. 2021 Nov 7;11(11):1156. doi: 10.3390/jpm11111156.
6
The Application Value of Lipoprotein Particle Numbers in the Diagnosis of HBV-Related Hepatocellular Carcinoma with BCLC Stage 0-A.脂蛋白颗粒数量在BCLC 0-A期乙肝相关肝细胞癌诊断中的应用价值
J Pers Med. 2021 Nov 4;11(11):1143. doi: 10.3390/jpm11111143.
7
The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer.白细胞介素6样细胞因子家族：在乳腺癌中的作用及作为生物标志物的潜力
J Pers Med. 2021 Oct 24;11(11):1073. doi: 10.3390/jpm11111073.
8
Low Preoperative Lymphocyte-to-Monocyte Ratio Is Predictive of the 5-Year Recurrence of Bladder Tumor after Transurethral Resection.术前低淋巴细胞与单核细胞比值可预测经尿道膀胱肿瘤切除术后5年复发情况。
J Pers Med. 2021 Sep 23;11(10):947. doi: 10.3390/jpm11100947.
9
A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer.一种发现乳腺癌放疗反应生物标志物的新方法。
J Pers Med. 2021 Aug 14;11(8):796. doi: 10.3390/jpm11080796.
10
Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.前列腺癌精准医学中的组织和液体生物标志物
J Pers Med. 2021 Jul 15;11(7):664. doi: 10.3390/jpm11070664.
Zotero 插件